Drug intelligence / Profile preview

asp5878

Development stage
Phase 1
Lead developer
Astellas Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

ASP5878 is an orally bioavailable, selective small-molecule inhibitor of fibroblast growth factor receptors (FGFRs) 1, 2, 3, and 4. It acts as a pan-FGFR antagonist with potent antineoplastic activity by inhibiting the kinase activity of these receptors. Preclinical studies demonstrated that ASP5878 suppresses cell proliferation in cancer cell lines harboring FGFR3 mutations or fusions and retains efficacy even in chemoresistant models. The drug was developed primarily for the treatment of solid tumors such as urothelial carcinoma and has also been investigated for achondroplasia. Clinical trials included patients with various solid tumors exhibiting FGFR genetic alterations[1][2][3][4][5][6].

Other names
FGFR inhibitor ASP5878
02

Targets

FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on asp5878.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on asp5878.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call